| Drug General Information |
| Drug ID |
D0AG7N
|
| Former ID |
DCL001211
|
| Drug Name |
MEDI-575
|
| Drug Type |
Antibody
|
| Indication |
Glioblastoma multiforme [ICD9: 191; ICD10:C71]
|
Phase 2 |
[1]
|
|---|
| Company |
MedImmune
|
| Target and Pathway |
| Target(s) |
Alpha platelet-derived growth factor receptor |
Target Info |
|
[1]
|
|---|
|
KEGG Pathway
|
MAPK signaling pathway
|
|
Ras signaling pathway
|
|
Rap1 signaling pathway
|
|
Calcium signaling pathway
|
|
Cytokine-cytokine receptor interaction
|
|
Endocytosis
|
|
PI3K-Akt signaling pathway
|
|
Focal adhesion
|
|
Gap junction
|
|
Regulation of actin cytoskeleton
|
|
HTLV-I infection
|
|
Pathways in cancer
|
|
MicroRNAs in cancer
|
|
Glioma
|
|
Prostate cancer
|
|
Melanoma
|
|
Central carbon metabolism in cancer
|
|
Choline metabolism in cancer
|
|
NetPath Pathway
|
TGF_beta_Receptor Signaling Pathway
|
|
PANTHER Pathway
|
Angiogenesis
|
|
PDGF signaling pathway
|
|
Pathway Interaction Database
|
ATF-2 transcription factor network
|
|
PDGFR-alpha signaling pathway
|
|
PDGF receptor signaling network
|
|
Reactome
|
PIP3 activates AKT signaling
|
|
Constitutive Signaling by Aberrant PI3K in Cancer
|
|
RAF/MAP kinase cascade
|
|
WikiPathways
|
Regulation of Actin Cytoskeleton
|
|
Osteoblast Signaling
|
|
Focal Adhesion
|
|
Hair Follicle Development: Organogenesis (Part 2 of 3)
|
|
PIP3 activates AKT signaling
|
|
Cardiac Progenitor Differentiation
|
|
Integrated Pancreatic Cancer Pathway
|
|
Allograft Rejection
|
|
Signaling Pathways in Glioblastoma
|
|
Signaling by PDGF
|
|
Angiogenesis
|
| References |
| REF 1 | Clinical pipeline report, company report or official report of MedImmune (2011). |
|---|
